AstraZeneca Trial Over Generic Nexium Delay Heading to Jury
This article is for subscribers only.
AstraZeneca Plc will soon learn whether it faces billions of dollars in damages for paying a generic-drug maker to delay copies of its blockbuster heartburn tablet Nexium in the first such trial since the U.S. Supreme Court ruled consumers can sue over pay-to-delay deals.
The case against AstraZeneca and the Indian generics maker Ranbaxy Laboratories Ltd. challenges a 2008 settlement of a patent lawsuit that stalled sales of a cheaper version of Nexium in the U.S. until AstraZeneca’s patents expired last May.